Le taux de rétention est un indicateur essentiel du programme. C’est une occasion pour les différents acteurs d’évaluer les progrès réalisés dans le maintien en vie des adultes et des enfants infectés qui sont mis sous traitement antirétroviral pendant une période déterminée.
Evaluation report
April 2013
Evaluation report
This report is part of the overall Ukrainian National AIDS programme evaluation conducted
in September 2012
Journal of the International AIDS Society 2017, 20(Suppl 4):21644
National AIDS Programme in Myanmar has made significant progress in scaling up antiretroviral treatment (ART) services and recognizes the importance of differentiated care for people living with HIV. Indeed, long centred around t...he hospital and reliant on physicians, the country's HIV response is undergoing a process of successful decentralization with HIV care increasingly being integrated into other health services as part of a systematic effort to expand access to HIV treatment. This study describes implementation of differentiated care in Médecins Sans Frontières (MSF)‐supported programmes and reports its outcomes.
https://doi.org/10.7448/IAS.20.5.21644
more
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
Conflict and Health 2015, 9:8 doi:10.1186/s13031-015-0035-8
Int J Health Policy Manag 2017, 6(10), 587–600
Low-income countries face many contextual challenges to manage healthcare technologies effectively, as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology management (HTM) policies in Benin ha...ve failed to produce better quality of care for the population and cost-effectiveness for the government. This study aims to identify and assess the main problems facing HTM in Benin’s public health sector, as well as the ability of key actors within the sector to address these problems.
more
Regulation of the Minister of Health of the Republic of Indonesia concerning guidelines for implementation of opioid replacement therapy program
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0